Lyell Immunopharma
A Vice President, Clinical Development at Lyell leads clinical development programs for next-generation CAR T-cell therapies in oncology. The role involves strategic leadership, regulatory expertise, and cross-functional collaboration to advance innovative cancer treatments.
Headquarters
South San Francisco, California, United States
Company Size
201-500 employees
Founded
2018
Lyell is a fully integrated biopharmaceutical company developing next‑generation T‑cell reprogramming technologies to create durable CAR T‑cell therapies for hematologic malignancies and solid tumors. Their platform-driven approach spans discovery through clinical development, with active programs and trials such as the PiNACLE study for aggressive B‑cell non‑Hodgkin lymphoma and the recently acquired GCC‑targeted candidate LYL273. Lyell is patient‑focused, aiming to improve outcomes for cancers with significant unmet medical need.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Lyell Immunopharma.
75% above the average for this role
HC Wainwright & Co. Maintains Lyell Immunopharma (LYEL) Neutral Recommendation
5 days ago
Open Rank Faculty Position in Pediatric Hematology/Oncology
University of North Carolina System
Sr Medical Science Liaison
Gilead Sciences
Pediatric Hematology/Oncology Faculty
Medical University of South Carolina (MUSC)
Associate Director / Director, Clinical Development
immunomeinc
Malignant Hematology Specialist With Cellular Therapy Interest
Atlantic Health System
Malignant Hematology Specialist with Cellular Therapy Interest
Atlantic Health System